{
    "2021-08-27": [
        [
            {
                "time": "",
                "original_text": "华大基因净利润降三成 新冠检测试剂“降价”后如何打造增长曲线 盈利能力下降",
                "features": {
                    "keywords": [
                        "华大基因",
                        "净利润",
                        "新冠检测试剂",
                        "降价",
                        "增长曲线",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "华大基因上半年净利同比降超三成：收入较去年疫情突发时略降 盈利能力下降",
                "features": {
                    "keywords": [
                        "华大基因",
                        "上半年",
                        "净利",
                        "同比下降",
                        "疫情",
                        "收入下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "华大基因上半年净利润逾10亿元 打造“平疫结合”双业务模式",
                "features": {
                    "keywords": [
                        "华大基因",
                        "上半年",
                        "净利润",
                        "10亿元",
                        "平疫结合",
                        "双业务模式"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}